
    
      This is a Phase 2, multicenter, randomized, open-label, sponsor-blind, active-controlled,
      dose-ranging trial of female subjects with an acute moderate to severe episode of
      vulvovaginal candidiasis. Subjects will be randomized to 1 of 3 treatment arms; CD101 gel,
      CD101 ointment, or oral fluconazole. After randomization, subjects will be seen on Day 7
      (+/-2 days), Day 14 (+/- 2 days), & Day 28 (+/-7 days) to assess therapeutic cure and safety.
    
  